Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · IEX Real-Time Price · USD
2.600
+0.060 (2.36%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Oramed Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Aug 31, 2021 | Dec 31, 2020 | 2019 - 2014 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.67 | 1.34 | 2.7 | 2.71 | 2.7 | 2.71 | Upgrade
|
| Revenue Growth (YoY) | -75.06% | -50.43% | -0.33% | 0.33% | -0.33% | 0.07% | Upgrade
|
| Gross Profit | 0.67 | 1.34 | 2.7 | 2.71 | 2.7 | 2.71 | Upgrade
|
| Selling, General & Admin | 8.47 | 8.14 | 15.66 | 12.58 | 5.94 | 4.73 | Upgrade
|
| Research & Development | 5.72 | 8.97 | 27.64 | 27.11 | 20.99 | 20.67 | Upgrade
|
| Operating Expenses | 14.2 | 17.11 | 43.3 | 39.69 | 26.93 | 25.4 | Upgrade
|
| Operating Income | -13.52 | -15.77 | -40.6 | -36.98 | -24.22 | -22.68 | Upgrade
|
| Interest Expense | -2.63 | -2.04 | - | - | - | -0.07 | Upgrade
|
| Interest & Investment Income | 7.97 | 8.03 | 3.57 | 0.47 | 0.35 | 0.78 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.12 | -0.12 | 0.18 | -0.03 | -0 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -1.4 | -1.4 | -0.01 | -0.01 | -0.01 | - | Upgrade
|
| EBT Excluding Unusual Items | -9.71 | -11.3 | -36.86 | -36.55 | -23.88 | -21.97 | Upgrade
|
| Gain (Loss) on Sale of Investments | 19.94 | 16.39 | -0.81 | -0.22 | 0.9 | - | Upgrade
|
| Pretax Income | 10.23 | 5.09 | -37.66 | -36.77 | -22.99 | -21.97 | Upgrade
|
| Income Tax Expense | - | - | 0.1 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | 10.23 | 5.09 | -37.76 | -36.77 | -22.99 | -21.97 | Upgrade
|
| Minority Interest in Earnings | 0.22 | 0.44 | 1.2 | 1.76 | 0.75 | - | Upgrade
|
| Net Income | 10.46 | 5.53 | -36.56 | -35 | -22.24 | -21.97 | Upgrade
|
| Net Income to Common | 10.46 | 5.53 | -36.56 | -35 | -22.24 | -21.97 | Upgrade
|
| Shares Outstanding (Basic) | 41 | 40 | 39 | 37 | 28 | 24 | Upgrade
|
| Shares Outstanding (Diluted) | 41 | 41 | 39 | 37 | 28 | 24 | Upgrade
|
| Shares Change (YoY) | 4.09% | 4.02% | 5.08% | 30.36% | 16.71% | 18.81% | Upgrade
|
| EPS (Basic) | 0.26 | 0.14 | -0.94 | -0.94 | -0.78 | -0.90 | Upgrade
|
| EPS (Diluted) | 0.26 | 0.14 | -0.94 | -0.94 | -0.78 | -0.90 | Upgrade
|
| Free Cash Flow | -6.28 | -10.55 | -28.41 | -33.39 | -21.56 | -25.75 | Upgrade
|
| Free Cash Flow Per Share | -0.15 | -0.26 | -0.73 | -0.90 | -0.76 | -1.06 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -2006.38% | -1176.79% | -1501.96% | -1363.50% | -896.15% | -836.39% | Upgrade
|
| Profit Margin | 1551.34% | 412.31% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -931.60% | -787.24% | -1051.20% | -1231.31% | -797.48% | -949.45% | Upgrade
|
| EBITDA | -13.31 | -15.57 | -40.54 | -36.92 | -24.15 | -22.66 | Upgrade
|
| D&A For EBITDA | 0.22 | 0.2 | 0.06 | 0.05 | 0.08 | 0.02 | Upgrade
|
| EBIT | -13.52 | -15.77 | -40.6 | -36.98 | -24.22 | -22.68 | Upgrade
|
Source: S&P Capital IQ. Standard template.